On Thursday, Inari Medical Inc. (NASDAQ: NARI) shares received an Outperform rating from William Blair, as the firm began coverage on the medical device company's stock. The optimism is based on Inari's significant presence in large, underpenetrated markets and the anticipation of influential clinical data from ongoing trials.
Inari Medical is currently conducting three pivotal trials, with the first, named PEERLESS, anticipated to present its findings in the coming months. Moreover, the company is expected to announce a fourth trial focused on high-risk pulmonary embolism (PE) shortly.
Previous results from large-scale registries have highlighted the clinical advantages of Inari's ClotTriever and FlowTriever devices. The firm posits that positive outcomes from the forthcoming randomized controlled trials (RCTs) could lead to increased adoption of Inari's products within the venous markets where the company currently operates.
The analyst from William Blair cited the upcoming clinical data catalysts as a key factor for the positive outlook on Inari Medical's stock, suggesting that the trial results could play a significant role in the company's future growth and market penetration.
Inari Medical specializes in the development of medical devices designed for the treatment of venous diseases. Its ClotTriever and FlowTriever systems are used for thrombectomy procedures, which are minimally invasive treatments to remove blood clots from vessels.
The Outperform rating is a bullish signal to investors, reflecting a belief that Inari Medical's stock will perform better than the average return of the stocks analyzed by the analyst's firm. This rating is particularly relevant as the company approaches the release of its clinical trial results, which could potentially enhance its market position and investor sentiment.
In other recent news, Inari Medical reported a significant 23% year-over-year increase in revenue, reaching $143.2 million, primarily due to U.S. core venous thromboembolism (VTE) treatments. This strong performance led the company to raise its full-year revenue guidance to between $592.5 million and $602.5 million. Still, a GAAP operating loss of $17.2 million was reported due to several deal-related expenses.
Investment firm Needham downgraded Inari Medical's stock from Buy to Hold, citing anticipated competition in the venous thrombectomy market and potential market share loss to competitor, Penumbra (NYSE:PEN). Analysts from Truist Securities, Baird, Piper Sandler, Canaccord Genuity, and Needham have adjusted their price targets for Inari Medical, reflecting a mix of optimism and caution.
Inari Medical is focusing on three key growth drivers: VTE treatments, Emerging Therapies, and international expansion, with plans to enter new markets such as China and Japan later this year. These are recent developments that could influence the company's future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.